Inebilizumab: Anti-CD19 MAb, treatment of neuromyelitis optica, treatment of relapsing-remitting multiple sclerosis, treatment of B-cell malignancies

B Cell Epitope Mapping of Aquaporin-4 (AQP4) and Reactivity to AQP4 Epitopes in Neuromyelitis Optica (NMO) and Relapsing-Remitting Multiple Sclerosis (RRMS) (P02.131)

Neurology ◽

10.1212/wnl.78.1_meetingabstracts.p02.131 ◽

2012 ◽

Vol 78 (Meeting Abstracts 1) ◽

pp. P02.131-P02.131

Author(s):

H. Alexopoulos ◽

E. Kampylafka ◽

I. Chatzi ◽

C. Karageorgiou ◽

M. Dalakas ◽

...

Keyword(s):

Multiple Sclerosis ◽

B Cell ◽

Neuromyelitis Optica ◽

Epitope Mapping ◽

Cell Epitope ◽

Aquaporin 4 ◽

B Cell Epitope ◽

Relapsing Remitting ◽

Relapsing Remitting Multiple Sclerosis

Primary mediastinal large B-cell lymphoma in a patient on Fingolimod for relapsing-remitting multiple sclerosis

Multiple Sclerosis and Related Disorders ◽

10.1016/j.msard.2021.102776 ◽

2021 ◽

Vol 49 ◽

pp. 102776

Author(s):

Joseph A Chacko ◽

Paolo Strati ◽

Paul W Stout ◽

Robert L Archer ◽

Brad P Baltz ◽

...

Keyword(s):

Multiple Sclerosis ◽

B Cell ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

Large B Cell Lymphoma ◽

Relapsing Remitting ◽

Large B Cell

The brain antigen-specific B cell response correlates with glatiramer acetate responsiveness in relapsing-remitting multiple sclerosis patients

Scientific Reports ◽

10.1038/srep14265 ◽

2015 ◽

Vol 5 (1) ◽

Cited By ~ 5

Author(s):

Damiano M. Rovituso ◽

Cathrina E. Duffy ◽

Michael Schroeter ◽

Claudia C. Kaiser ◽

Christoph Kleinschnitz ◽

...

Keyword(s):

Multiple Sclerosis ◽

B Cell ◽

Glatiramer Acetate ◽

Cell Response ◽

Brain Antigen ◽

Relapsing Remitting ◽

Multiple Sclerosis Patients ◽

The Brain

Cost-Effectiveness of Natalizumab Compared With Fingolimod for Relapsing-Remitting Multiple Sclerosis Treatment in Colombia

Value in Health Regional Issues ◽

10.1016/j.vhri.2019.08.481 ◽

2020 ◽

Vol 23 ◽

pp. 13-18 ◽

Cited By ~ 1

Author(s):

Pieralessandro Lasalvia ◽

Fabián Hernández ◽

Camilo Castañeda-Cardona ◽

J. Andrés Cuestas ◽

Diego Rosselli

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Relapsing Remitting ◽

Antibody-independent B cell effector functions in relapsing remitting Multiple Sclerosis: Clues to increased inflammatory and reduced regulatory B cell capacity

Autoimmunity ◽

10.3109/08916934.2012.665529 ◽

2012 ◽

Vol 45 (5) ◽

pp. 400-414 ◽

Cited By ~ 41

Author(s):

Sara J. Ireland ◽

Monica Blazek ◽

Christopher T. Harp ◽

Benjamin Greenberg ◽

Elliot M. Frohman ◽

...

Keyword(s):

Multiple Sclerosis ◽

B Cell ◽

Regulatory B Cell ◽

Effector Functions ◽

Cell Capacity ◽

Relapsing Remitting ◽

Cell Effector

Relapsing Neuromyelitis Optica and Relapsing-Remitting Multiple Sclerosis: Differentiation at Diffusion-Tensor MR Imaging of Corpus Callosum

Radiology ◽

10.1148/radiol.2441060930 ◽

2007 ◽

Vol 244 (1) ◽

pp. 249-256 ◽

Cited By ~ 31

Author(s):

Chun Shui Yu ◽

Chao Zhe Zhu ◽

Kun Cheng Li ◽

Yun Xuan ◽

Wen Qin ◽

...

Keyword(s):

Multiple Sclerosis ◽

Corpus Callosum ◽

Mr Imaging ◽

Neuromyelitis Optica ◽

Diffusion Tensor ◽

Relapsing Remitting ◽

Diffusion Tensor Mr Imaging

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

Current Neurology and Neuroscience Reports ◽

10.1007/s11910-008-0064-4 ◽

2008 ◽

Vol 8 (5) ◽

pp. 417-418 ◽

Cited By ~ 11

Author(s):

Dennis Bourdette ◽

Vijayshree Yadav

Keyword(s):

Multiple Sclerosis ◽

B Cell ◽

Cell Depletion ◽

B Cell Depletion ◽

Relapsing Remitting ◽

Relapsing Remitting Multiple Sclerosis

Cost-effectiveness of alemtuzumab and natalizumab for relapsing-remitting multiple sclerosis treatment in Iran: decision analysis based on an indirect comparison

Journal of Medical Economics ◽

10.1080/13696998.2018.1543189 ◽

2018 ◽

Vol 22 (1) ◽

pp. 71-84 ◽

Cited By ~ 3

Author(s):

Saeed Taheri ◽

Mohammad Ali Sahraian ◽

Nazila Yousefi

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Decision Analysis ◽

Indirect Comparison ◽

Relapsing Remitting ◽

Faculty Opinions recommendation of B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1104283.560289 ◽

2008 ◽

Author(s):

Myla Goldman

Keyword(s):

Multiple Sclerosis ◽

B Cell ◽

Cell Depletion ◽

B Cell Depletion ◽

Relapsing Remitting ◽

Relapsing Remitting Multiple Sclerosis

Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients

Journal of Neurology Neurosurgery & Psychiatry ◽

10.1136/jnnp.2007.124958 ◽

2008 ◽

Vol 79 (1) ◽

pp. 52-56 ◽

Cited By ~ 84

Author(s):

E. Le Page ◽

E. Leray ◽

G. Taurin ◽

M. Coustans ◽

J. Chaperon ◽

...

Keyword(s):

Multiple Sclerosis ◽

Observational Study ◽

Treatment Response ◽

Induction Treatment ◽

Response Factors ◽

Relapsing Remitting ◽